Top 50 Biotech VC Funds & Investors (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
261 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
ARCH Venture Partners
VC Fund
|
142 | United States, China, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $7.8M–$250M |
|
OrbiMed
VC Fund
|
118 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$150M |
|
Sofinnova Partners
VC Fund
|
111 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$120M |
|
Alexandria Venture Investments
VC Fund
|
110 | United States, Canada, France | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$150M |
|
Novo Holdings
VC Fund
|
101 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9M–$130M |
|
Qiming Venture Partners
VC Fund
|
87 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5M–$142M |
|
Versant Ventures
VC Fund
|
85 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$108M |
|
Bpifrance
VC Fund
|
85 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $694k–$35M |
|
F-Prime
VC Fund
|
84 | United States, United Kingdom, China | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $9.2M–$130M |
|
Atlas Venture
VC Fund
|
80 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.2M–$115M |
|
RA Capital Management
VC Fund
|
78 | United States, United Kingdom, Canada | Series B, Series C, Post-IPO Equity | Biotechnology, Health Care, Therapeutics | $26M–$235M |
|
New Enterprise Associates
VC Fund
|
77 | United States, India, United Kingdom | Series A, Series B, Series C | Software, Health Care, Biotechnology | $5.3M–$103M |
|
Khosla Ventures
VC Fund
|
75 | United States, India, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, Health Care | $2M–$100M |
|
Polaris Partners
VC Fund
|
70 | United States, Ireland, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $4.5M–$107M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
70 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$40M |
|
M Ventures
VC Fund
|
69 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Novartis Venture Fund
VC Fund
|
67 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$120M |
|
5AM Ventures
VC Fund
|
66 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $13M–$110M |
|
MPM Capital
VC Fund
|
65 | United States, Canada, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $9M–$125M |
|
Innova Memphis
VC Fund
|
63 | United States, Argentina, United Kingdom | Seed, Pre-Seed | Health Care, Medical, Medical Device | $25k–$1.7M |
|
Third Rock Ventures
VC Fund
|
62 | United States | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$150M |
|
Google Ventures
VC Fund
|
60 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1M–$107M |
|
UK Innovation & Science Seed Fund
VC Fund
|
59 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $393k–$14M |
|
Alumni Ventures
VC Fund
|
58 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.4M–$79M |
|
Forbion Capital Partners
VC Fund
|
57 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $15M–$176M |
|
HSG
VC Fund
|
56 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $4.4M–$214M |
|
Lilly Asia Ventures
VC Fund
|
56 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$259M |
|
Canaan Partners
VC Fund
|
55 | United States, United Kingdom, Israel | Series A, Series B, Series C | Software, Biotechnology, Health Care | $5M–$75M |
|
Pfizer Venture Investments
VC Fund
|
55 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$123M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
54 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.3M–$50M |
|
SR One
VC Fund
|
53 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$150M |
|
Lux Capital
VC Fund
|
53 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.8M–$150M |
|
Andreessen Horowitz
VC Fund
|
53 | United States, United Kingdom, Brazil | Series A, Seed, Series B | Software, Information Technology, Artificial Intelligence | $1.5M–$107M |
|
BioAdvance
VC Fund
|
51 | United States, Canada | Seed, Series A | Biotechnology, Health Care, Medical | $200k–$40M |
|
Eli Lilly
VC Fund
|
50 | United States, United Kingdom, Canada | Series A, Series B | Biotechnology, Health Care, Medical | $6.5M–$175M |
|
Fifty Years
VC Fund
|
49 | United States, Germany, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Artificial Intelligence | $2M–$91M |
|
Gaingels
VC Fund
|
49 | United States, Canada, Mexico | Seed, Series A, Series B | Software, Health Care, Artificial Intelligence | $1.4M–$100M |
|
Omega Funds
VC Fund
|
48 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Seventure Partners
VC Fund
|
48 | France, United States, Germany | Series A, Series B | Biotechnology, Health Care, Software | $3.1M–$65M |
|
DCVC
VC Fund
|
47 | United States, Canada, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, Machine Learning | $1.5M–$130M |
|
Takeda Ventures
VC Fund
|
47 | United States, United Kingdom, Israel | Series A, Series B | Biotechnology, Health Care, Therapeutics | $10M–$130M |
|
Parkwalk Advisors
VC Fund
|
47 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $982k–$46M |
|
KdT Ventures
VC Fund
|
47 | United States, India, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $2.6M–$175M |
|
Scottish Enterprise
VC Fund
|
46 | United Kingdom, United States, Japan | Grant, Seed | Biotechnology, Software, Health Care | $104k–$4.8M |
|
Sofinnova Investments
VC Fund
|
46 | United States, France, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $7.3M–$137M |
|
The Column Group
VC Fund
|
46 | United States | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $9.2M–$120M |
|
EQT Life Sciences
VC Fund
|
45 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.9M–$165M |
|
Mission BioCapital
VC Fund
|
43 | United States, Switzerland, France | Series A, Series B | Biotechnology, Health Care, Therapeutics | $4.2M–$112M |
|
Casdin Capital
VC Fund
|
43 | United States, China, France | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$200M |
| Access all 15682 VC funds in Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 387
- Round size: Series A $7.8M–$212M; Series B $13M–$250M; Series C $15M–$175M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Ultivue — Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts.
- EGenesis — At eGenesis, we envision a world where transplantation is accessible to all. We develop safe and effective human-compatible organs for transplantation.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 588
- Round size: Series A $10M–$116M; Series B $24M–$150M; Series C $15M–$143M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.
- Insilico Medicine — Artificial Intelligence for Drug Discovery and Aging Research
- Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 308
- Round size: Series A $6M–$67M; Series B $10M–$120M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- EndoRon Medical — Endoron Medical develops an endovascular suture, like a device for the effective treatment of an abdominal aortic aneurysm.
- BrightHeart — BrightHeart develops an AI-based platform for fetal ultrasound analysis to improve detection of congenital heart defects.
- Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, France
Investor stats
- Total investments: 246
- Round size: Seed $2M–$31M; Series A $12M–$100M; Series B $25M–$150M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- miRecule — MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
- Marvin Health — Marvin is a mental health service for physicians. We're ending the one-size-fits-all approach to teletherapy, helping you to set a teletherapy action plan.
- Deep Genomics — Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 334
- Round size: Series A $9M–$120M; Series B $12M–$130M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- AlloCure — AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany.The company isdedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.
- PTC Therapeutics — Translating Science. Transforming Lives.
- Breye Therapeutics — Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 739
- Round size: Series A $5M–$64M; Series B $10M–$100M; Series C $15M–$142M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $887M in 2023
Portfolio highlights
- Duet — Duet is a dating application helps you find meaningful relationships based on shared interests and experiences.
- SPEEDIANCE — Speediance specializes on smart self-serviced gym equipment. The company develops smart fitness equipment and an online platform to provide training guidance and courses about strength training, enabling individual users to connect with the workout community and have better home workout experiences.
- moodytiger — Technology-Driven & Design-Led Activewear for Kids moodytiger aims to create revolutionary activewear that is comfortable, multi-functional, and stylish for children aged from 4 to 14 years old.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 282
- Round size: Series A $4.7M–$80M; Series B $10M–$105M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Stablix — Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1069
- Round size: Seed $694k–$6.9M; Series A $2.6M–$35M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Verkor — Verkor is a battery cell manufacturer whose goal is to increase the production of low-carbon batteries to fulfill the growing demand for electric vehicles. The company focuses on the development of low-carbon batteries with a carbon footprint that is many times smaller than standard batteries. This reduces the logistics footprint, includingemissions, and provides businesses with batteries that are very inexpensive and use carbon-free electricity.
- WAAT — WAAT operates fast charging stations for electric and rechargeable hybrid vehicles. Its services are aimed at all private sector market segments, including condominiums, lessees, tertiary, and real estate development. The company was founded in 2018 and is based in Paris with sales offices in Malakoff and Bagneux (92).
- BiPER Therapeutics — BiPER Therapeutics is a biotech company to develop and commercializes novel therapeutics.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 422
- Round size: Series A $9.2M–$87M; Series B $16M–$130M; Series C $22M–$115M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- 1upHealth — 1upHealth is the trusted interoperability solutions provider for health plans looking to acquire, manage, exchange, analyze, and use clinical data and claims data.
- Simon Data — Simon Data empowers CRM teams with the data, tools, & support to drive personalization at every customer touchpoint.
- CHARM Therapeutics — CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 418
- Round size: Series A $3.2M–$75M; Series B $8M–$115M; Series C $6M–$95M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
- Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
- Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 447
- Round size: Series B $26M–$152M; Series C $40M–$200M; Post-IPO Equity $34M–$235M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
- Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1539
- Round size: Series A $5.3M–$60M; Series B $10M–$80M; Series C $13M–$103M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $2.8B in 2022
Portfolio highlights
- Perplexity — Perplexity is a search engine platform that uses artificial intelligence to provide large language models and search engines. The company's platform enables the development of beneficial artificial general intelligence, as well as an open-source environment that is accessible to the public, allowing clients to develop skills and knowledge inartificial intelligence.
- Allay Therapeutics — SUPPORTING PATIENTS THROUGH EVERY PHASE OF RECUPERATION The first technology designed to deliver weeks of localized pain management
- Regulus Therapeutics — Regulus Therapeutics Is a biopharmaceutical company leading the discovery of a new class of high-impact medicines based on microRNAs. The discovery of MicroRNA in humans is one of the most exciting scientific breakthroughs in the last decade. MicroRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteinsbut instead regulate gene expression. It was founded in 2007 and is headquartered in Carlsbad, California.
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1084
- Round size: Seed $2M–$17M; Series A $5.5M–$44M; Series B $10M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $557M in 2022
Portfolio highlights
- Caelux — Solar: Amplified Caelux is a pioneer in utilizing perovskites to make solar energy more powerful and cost-effective, enabling the next generation of solar innovation. PV 3.0 is Here. As competing technologies battle it out to improve solar return on
- Even — Even is a health tech company and healthcare provider that partners directly with the top hospitals in the country to offer you unlimited diagnostics, consultations, and 50 lakh worth of hospitalisations all with one monthly subscription cost.
- Loop — Loop Health is bringing ease and choice to patients seeking major medical treatments. We've brought together family physicians, top specialists, and leading hospitals in Pune – to provide options, transparency, and ease to patients and their families. Loop Coordinators help patients match with a doctor, compare treatment costs, get secondopinions, and complete admission formalities – removing the stress and making lives easier for the patient and their families.
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Ireland, Singapore
Investor stats
- Total investments: 450
- Round size: Series A $4.5M–$80M; Series B $7M–$107M; Series C $10M–$100M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $182M in 1998
Portfolio highlights
- Thirty Madison — Thirty Madison is a human-first healthcare company, powering access to affordable specialized healthcare through brands like Keeps and Cove.
- CliQr Technologies — CliQr is a leading provider of application-defined cloud management solutions. Offering full lifecycle management delivered in a single, intuitive packaged platform, CliQr enables businesses to easily and efficiently model, deploy and manage one to many applications, users, and clouds.CliQr’s application-defined technology de-couplesapplications from the complexity of hybrid cloud environments, allowing them to securely move, deploy and manage new and existing application across any physical, virtual or cloud environment.CliQr’s patented and patent-pending technology and its global partners help dozens of leading brands in healthcare, manufacturing and technology markets manage their cloud application lifecycles in over 15 different data center, private and public cloud environments.Headquartered in San Jose, California, with locations in Canada, India and Czech Republic, CliQr is backed by Polaris Partners, Foundation Capital, Google Ventures and TransLink Capital. For additional information, visit www.cliqr.com.
- Invivyd — Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patientsand clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with thirdparty contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 555
- Round size: Seed $909k–$7.4M; Series A $3M–$40M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- TRAIT — TRAIT Running Coach app for your iphone or ipad tablet.
- Certivity — Certivity offers software to model digital regulatory twins of their products. This will ensure that current regulatory requirements are integrated in the right place in the engineering process. Product compliance will be smarter, safer, more transparent, more efficient, and significantly cheaper.
- Scavenger AI — Scavenger AI helps businesses transform complex data into clear, actionable insights.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 170
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
- Biolinq — Introducing a revolutionary platform for metabolic health.
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 213
- Round size: Series A $5.1M–$81M; Series B $11M–$120M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
- LOQUS23 THERAPEUTICS — LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 178
- Round size: Series A $13M–$70M; Series B $16M–$110M; Series C $14M–$100M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — raised $450M in 2022
Portfolio highlights
- Neurogastrx — Neurogastrx, Inc. is a venture-stage biopharmaceutical company developing products for the treatment of gastrointestinal disorders.
- Vor Biopharma — Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. Our goal is to bring life-changing therapies to patients worldwide who are living with serious, autoantibody-driven conditions.
- Cleave Therapeutics — Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.
Powering Breakthroughs in Life Sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 225
- Round size: Series A $9M–$84M; Series B $20M–$125M; Series C $12M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $850M in 2021
Portfolio highlights
- Chiasma — We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare diseases.
- Syndax Pharmaceuticals — Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
- Portola Pharmaceuticals — As Alexion, AstraZeneca Rare Disease, we are delivering life-changing therapies to people living with rare diseases.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Pre-Seed
- Geography: United States, Argentina, United Kingdom
Investor stats
- Total investments: 251
- Round size: Seed $50k–$1.7M; Pre-Seed $25k–$1.3M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
- Insignum AgTech — Insignum AgTech develops biotech plants that communicate with producers, alerting them to an illness in its early stages.
- Rescue Forensics — Customer service is our #1 priority. Get a premium domain for your website today. Financing available.
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States
Investor stats
- Total investments: 148
- Round size: Series A $17M–$110M; Series B $11M–$150M; Series C $14M–$146M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
- Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
- Synnovation Therapeutics — Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small-molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1029
- Round size: Seed $1M–$15M; Series A $5.4M–$88M; Series B $15M–$107M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Smarterer — Individuals and Fortune 500 companies use Smarterer to help close the gap between the skills they have and the skills they need. Their dynamic assessment engine leverages the freshest crowdsourced tests around, to rapidly pinpoint skill level with a credible score. In November 2014, Pluralsight, the global leader in online learning for serioussoftware developers, IT specialists and creative technologists, acquired Smarterer. As the world's largest curated e-learning library for professionals, the company offers instant access to more than 3,500 courses authored by top experts. Smarterer will continue to power crowdsourced assessments for freelancer marketplaces, e-learning providers and enterprise companies anywhere people need to prove their skills to connect with professional opportunities. The Smarterer community has answered over 56 million during 1.7 million test sessions, across hundreds of tests.
- Zest — Give your shoppers the swiftest gifting experience in ecommerce. With Zest, shoppers on your site can send a gift to anybody, anywhere with just a link.
- EpiBiologics — EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 131
- Round size: Seed $393k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- HonuWorx — HonuWorx is a subsea robotics company founded with a mission to replace surface vessels with underwater deployment platforms.
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Aquark Technologies — Aquark Technologies develops atom systems to develop quantum applications, including atomic clocks, sensors, and navigation systems. Aquark develops a technique to miniaturize cold atom systems using unique laser geometry that is based on more than 10 years of proprietary research at the University of Southampton.
Access curated startup investment opportunities and diversified venture capital exposure designed for accredited investors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 1427
- Round size: Seed $1.4M–$10M; Series A $5.2M–$37M; Series B $12M–$79M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Jericho Security — Train your team to defend against the latest cyber attacks with our complete cybersecurity platform.
- Vouch — Vouch is a new kind of digital insurer that protects startups from mistakes, litigation and attack.
- Operative Intelligence — Drive impactful changes at every level of the business with eye-opening metrics that the c-suite will care about
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 187
- Round size: Series A $16M–$176M; Series B $15M–$155M; Series C $19M–$113M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
- Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 751
- Round size: Series A $4.4M–$100M; Series B $12M–$200M; Series C $26M–$214M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
- Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
- Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 211
- Round size: Series A $14M–$100M; Series B $25M–$112M; Series C $28M–$259M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- Ronovo Surgical — Founded in 2019 and headquartered in Shanghai, Ronovo Surgical is founded by industry veterans from global leaders in surgical and industrial robotics, such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA. Aiming to transform how surgery is performed in China, Ronovo is leveraging robust R&D capabilities and strategicpartnerships globally to accelerate the development of a broad portfolio of MIS and digital surgery solutions that exemplifies the core themes of simplicity, precision, and intelligence.
- Tmunity Therapeutics — Tmunity Therapeutics is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), universal engineered T cell platforms, and Chimeric Antigen....
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 655
- Round size: Series A $5M–$40M; Series B $7.8M–$75M; Series C $7.1M–$55M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $100M in 2024
Portfolio highlights
- Hermeus — Hermeus is developing hypersonic aircraft to connect the world faster than ever before.
- WorkMotion — WorkMotion offers Global HR Solutions to help companies navigate the New Ways of Working. Solutions fully compliant.
- Savvy — Savvy is a software development company that engages in cybersecurity.
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 166
- Round size: Series A $10M–$100M; Series B $20M–$123M; Series C $15M–$102M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $600M in 2018
Portfolio highlights
- Neuronetics — Antidepressant medications don't work for everyone. If drugs haven't worked for you, learn about NeuroStar - safe, effective, lasting TMS therapy for depression.
- Triana Biomedicines — Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 96
- Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 189
- Round size: Series A $3.7M–$140M; Series B $15M–$114M; Series C $22M–$150M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- River Vision Development — River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 520
- Round size: Seed $1.8M–$30M; Series A $7M–$60M; Series B $13M–$150M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $100M in 2007
Portfolio highlights
- Plexium — Plexium harnesses a differentiated platform of proprietary technologies and approaches to establish a robust and diverse portfolio.
- Clarifai — Clarifai is the leading Machine Learning, Computer Vision, NLP Platform. Label, train, deploy models on one AI platform for developers & data scientists.
- Primer — Primer makes powerful mission-ready AI software designed to work in your environment, on your data. We help national security teams sift through massive unstructured data sets to find the needle in the haystack, understand and visualize their data, and act collaboratively. Our mission is to empower decisions that can be defended, and acted upon confidently.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Brazil
Investor stats
- Total investments: 1629
- Round size: Seed $1.5M–$15M; Series A $9M–$53M; Series B $16M–$107M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Bounce — Luggage Storage Near Me 24/7 - Store your baggage in 32,000+ worldwide locations. Bounce is the BEST luggage storage app for finding and booking left luggage & lockers near you!
- Foodology — Foodology creates and operates digital restaurant brands made for delivery.The company aims to be a delivery-focused restaurant group in Latam. With its portfolio of virtual brands operated through cloud kitchens, Foodology strives to create a best in class delivery experience for its customers.The company was founded in 2019 by HarvardBusiness School classmates Daniela Izquierdo and Juan Guillermo Azuero.
- Shapeways — Shapeways is the #1 online 3D printing service company. Working with over a million customers since 2007 - Get 3D products and parts delivered to over 100 countries.
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United States, Canada
Investor stats
- Total investments: 118
- Round size: Seed $200k–$2.5M; Series A $3M–$40M
- Lead/follow: 14% lead, 86% follow
- Last fund: May invest from a new fund soon — raised $20M in 2002
Portfolio highlights
- Latus Bio — Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing.
- Tolerance Bio — Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergi
- Vittoria Biotherapeutics — Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.
Lilly is a medicine company that puts health above all. Learn about our medicines, view condition support, find care, and much more.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 125
- Round size: Series A $7M–$94M; Series B $6.5M–$175M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Cabaletta Bio — Cabaletta Bio discovers and develops targeted cell therapy product candidates to potentially cure patients with autoimmune diseases. Learn about our CAAR T cell products.
- Alchemab Therapeutics — Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
- United States Fund For Unicef — United States Fund For Unicef helps save and protect the world's most vulnerable children.
WE BACK HEROES using technology to solve the world's biggest problems
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Germany, Canada
Investor stats
- Total investments: 162
- Round size: Seed $2M–$15M; Series A $8.5M–$40M; Series B $16M–$91M
- Lead/follow: 18% lead, 82% follow
- Last fund: Likely still investing — raised $90M in 2021
Portfolio highlights
- Farcast — Unlocking satellite internet capacity through user terminal innovation
- Solugen — Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition.
- Valence Discovery — Empowering drug discovery scientists with the latest advances in AI-enabled drug design
Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital todate. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, Mexico
Investor stats
- Total investments: 754
- Round size: Seed $1.4M–$8M; Series A $6M–$40M; Series B $16M–$100M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Quadient Accounts Receivable by YayPay — YayPay accounts receivable automation software helps businesses collect faster, forecast cash flow accurately, and improve payment process. Automate your AR
- Sharper Sense — Neuromodulation for Clear Senses
- Multiverse Computing — World leaders in quantum computing for the financial industry. The first quantum & quantum-inspired toolbox for finance.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 149
- Round size: Series A $16M–$197M; Series B $35M–$162M; Series C $14M–$208M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
- NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 218
- Round size: Series A $3.1M–$24M; Series B $3.3M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Sentryc — Protect your brand and your products from counterfeiters with Sentryc. We monitor over 120 marketplaces for you and remove potential counterfeits.
- Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
- Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We are deep tech venture capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 383
- Round size: Seed $1.5M–$10M; Series A $5.7M–$45M; Series B $15M–$130M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $1B in 2023
Portfolio highlights
- ZwitterCo — ZwitterCo is revolutionizing water & wastewater treatment with cutting-edge membrane technology, along with providing sustainable, high-efficiency solutions.
- Jupiter Intelligence — The Trusted Leader in Climate Risk Analytics. Learn about our best-in-science solutions.
- Relation Therapeutics — Relation uses machine learning to develop drugs for pressing unmet need.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 104
- Round size: Series A $10M–$58M; Series B $20M–$130M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- StrideBio — StrideBio is a gene therapy company focused on developing genetic medicines with curative potential for patients with devastating conditions. It leverages its proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes toovercome current limitations of first-generation gene therapies. The company was founded in 2015 and is headquartered in Durham, North Carolina.
- Xilio Therapeutics — WhatsApp Group Invite
- Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 259
- Round size: Seed $982k–$5M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
- Bramble Energy — Bramble Energy is an innovator energy technology company that designs and manufactures high-performance, low-cost, and fuel cell stack. The company ability to leverage the global high-volume PCB industry means that they are the first fuel cell company with the manufacturing capacity to supply gigawatts of fuel cell hardware, something the batteryindustry has spent many years and £B’s to achieve.Bramble Energy specifically uses a printed circuit board (PCB) technology to form the structural parts of the fuel cell. It also provides products including modular PCBFC stacks, H20:20W PCBFC system, custom design PCBFC, and 500W PCBFC stack.Bramble Energy was founded in 2016 and is based in London, England, United Kingdom.
KdT Ventures is the standard for early-stage frontier science investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, India, Canada
Investor stats
- Total investments: 89
- Round size: Seed $2.6M–$13M; Series A $8.5M–$70M; Series B $25M–$175M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely still investing — raised $80M in 2022
Portfolio highlights
- Elegen — Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified and shipped globally in as few business days.
- Checkerspot — A biology-driven platform creating specialized lipids from fermentation
- Tierra Biosciences — Speed, scale and simplicity with protein synthesis on-demand. Discover your portal to thousands of custom proteins. Get testable material with a single input.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 311
- Round size: Seed $318k–$3.8M; Grant $104k–$4.8M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Incremental Group — Incremental Group provides software consultancy and analytics services to clients in oil and gas, financial services, and the public sector.
- RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
- Smart Green Shipping — smart green shipping alliance. economically, socially and environmentally superior shipping solutions.
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, France, Switzerland
Investor stats
- Total investments: 210
- Round size: Series A $7.3M–$100M; Series B $15M–$137M; Series C $15M–$94M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $650M in 2016
Portfolio highlights
- Invitae — Invitae and Labcorp together offer advanced genetic testing that can be easily integrated into medical practices. Improve patient care with meaningful insights based on DNA.
- Vera Therapeutics — Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential. The company's gene-editing technology can potentially cure patients with sickle cell disease, cystic fibrosis, and other devastating genetic disorders, enabling physicians to improve gene detection and regulation.
- Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States
Investor stats
- Total investments: 138
- Round size: Series A $9.2M–$102M; Series B $22M–$120M; Series C $33M–$107M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Exonics Therapeutics — Exonics’ laboratory has demonstrated the ability to use adeno-associated virus (AAV) to deliver a payload based on CRISPR/Cas9 technology that can identify and correct exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers.
- Revolution Medicines — Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois atUrbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology.REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.
- Constellation Pharmaceuticals — Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 174
- Round size: Series A $6.9M–$77M; Series B $12M–$103M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
- Neuros Medical — Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine.
- Simplify Medical — Simplify Medical designs, develops, and manufactures cervical artificial discs for use in the spine. It offers an MRI compatible motion preserving artificial cervical disc that is used to treat single level symptomatic cervical disc disease.The company provides its products for skeletally mature patients for reconstruction of the disc at onelevel from C3-C7 following single-level discectomy for intractable radiculopathy, such as arm pain or a neurological deficit.Simplify Medical was founded in 2015 and is based in Mountain View, California.
Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, Switzerland, France
Investor stats
- Total investments: 93
- Round size: Series A $4.2M–$80M; Series B $21M–$112M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely still investing — raised $275M in 2021
Portfolio highlights
- Umlaut.Bio — Decoding RNA modifications to revolutionize cancer and inflammation treatment. Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapeutic molecules to modify tRNA and target cancers and inflammatory diseases.
- Velocity Bio — Velocity Bio is a Stanford University spinout developing high-throughput platforms capable of selectivity-first allosteric drug discovery for under-drugged human enzymes implicated in devastating diseases.
- Bullseye Biosciences — Bullseye Biosciences is a therapeutics discovery company revolutionizing drug development through robotics and evolution. Our platform operationalizes cutting-edge directed evolution technology by incorporating automation and Next Generation Sequencing. By targeting challenging drivers of human dise
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, China, France
Investor stats
- Total investments: 190
- Round size: Series A $10M–$200M; Series B $32M–$150M; Series C $36M–$200M
- Lead/follow: 17% lead, 83% follow
- Last fund: May invest from a new fund soon — raised $30M in 2018
Portfolio highlights
- Adlai Nortye — Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment.
- Apella Technology — Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Biotech VC funding at a glance
Stats across 31k deals from 16k investors.
Access all 15682 VC funds in Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech VC Funds investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 15682 VC funds investing in Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!